Tags

Type your tag names separated by a space and hit enter

Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children.
Eur Rev Med Pharmacol Sci. 2016 11; 20(21):4601-4606.ER

Abstract

OBJECTIVE

Streptococcus salivarius K12 (BLIS K12) is a probiotic strain strongly antagonistic to the growth of Streptococcus pyogenes, the most important bacterial cause of pharyngeal infections in humans. Shown to colonize the oral cavity and to be safe for human use, BLIS K12 has previously been reported to reduce pharyngo-tonsillitis episodes in children or adults known to have experienced recurrent streptococcal infection. The present study was focussed upon evaluating the role of BLIS K12 in the control of streptococcal disease and acute otitis media in children attending the first year of kindergarten.

PATIENTS AND METHODS

By randomization, 222 enrolled children attending the first year of kindergarten were divided into a treated group (N = 111) receiving for 6 months a daily treatment with BLIS K12 (Bactoblis®) and a control group (N = 111) who were monitored as untreated controls. During the 6 months of treatment and 3 months of follow-up, the children were evaluated for treatment tolerance, and for episodes of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media.

RESULTS

During the 6-month trial (N = 111 per group) the incidence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media was approximately 16%, 9% and 44% respectively in the treated group and 48%, 4% and 80% in the control group. During the 3-months follow-up (N = 29 per group) the corresponding rates of infection were 15%, 0% and 12% in the treated group and 26%, 6% and 36% in the controls. No apparent side effects were detected in the treated group either during treatment or follow-up. All of the enrolled children completed the study.

CONCLUSIONS

The daily administration of BLIS K12 to children attending their first year of kindergarten was associated with a significant reduction in episodes of streptococcal pharyngitis and acute otitis media. No protection against scarlet fever was detected.

Authors+Show Affiliations

Scientific Department, Velleja Research, Milan, Italy. f.dipierro@vellejaresearch.com.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27874935

Citation

Di Pierro, F, et al. "Effect of Administration of Streptococcus Salivarius K12 On the Occurrence of Streptococcal Pharyngo-tonsillitis, Scarlet Fever and Acute Otitis Media in 3 Years Old Children." European Review for Medical and Pharmacological Sciences, vol. 20, no. 21, 2016, pp. 4601-4606.
Di Pierro F, Colombo M, Giuliani MG, et al. Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. Eur Rev Med Pharmacol Sci. 2016;20(21):4601-4606.
Di Pierro, F., Colombo, M., Giuliani, M. G., Danza, M. L., Basile, I., Bollani, T., Conti, A. M., Zanvit, A., & Rottoli, A. S. (2016). Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. European Review for Medical and Pharmacological Sciences, 20(21), 4601-4606.
Di Pierro F, et al. Effect of Administration of Streptococcus Salivarius K12 On the Occurrence of Streptococcal Pharyngo-tonsillitis, Scarlet Fever and Acute Otitis Media in 3 Years Old Children. Eur Rev Med Pharmacol Sci. 2016;20(21):4601-4606. PubMed PMID: 27874935.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. AU - Di Pierro,F, AU - Colombo,M, AU - Giuliani,M G, AU - Danza,M L, AU - Basile,I, AU - Bollani,T, AU - Conti,A M, AU - Zanvit,A, AU - Rottoli,A S, PY - 2016/11/23/entrez PY - 2016/11/23/pubmed PY - 2017/7/29/medline SP - 4601 EP - 4606 JF - European review for medical and pharmacological sciences JO - Eur Rev Med Pharmacol Sci VL - 20 IS - 21 N2 - OBJECTIVE: Streptococcus salivarius K12 (BLIS K12) is a probiotic strain strongly antagonistic to the growth of Streptococcus pyogenes, the most important bacterial cause of pharyngeal infections in humans. Shown to colonize the oral cavity and to be safe for human use, BLIS K12 has previously been reported to reduce pharyngo-tonsillitis episodes in children or adults known to have experienced recurrent streptococcal infection. The present study was focussed upon evaluating the role of BLIS K12 in the control of streptococcal disease and acute otitis media in children attending the first year of kindergarten. PATIENTS AND METHODS: By randomization, 222 enrolled children attending the first year of kindergarten were divided into a treated group (N = 111) receiving for 6 months a daily treatment with BLIS K12 (Bactoblis®) and a control group (N = 111) who were monitored as untreated controls. During the 6 months of treatment and 3 months of follow-up, the children were evaluated for treatment tolerance, and for episodes of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media. RESULTS: During the 6-month trial (N = 111 per group) the incidence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media was approximately 16%, 9% and 44% respectively in the treated group and 48%, 4% and 80% in the control group. During the 3-months follow-up (N = 29 per group) the corresponding rates of infection were 15%, 0% and 12% in the treated group and 26%, 6% and 36% in the controls. No apparent side effects were detected in the treated group either during treatment or follow-up. All of the enrolled children completed the study. CONCLUSIONS: The daily administration of BLIS K12 to children attending their first year of kindergarten was associated with a significant reduction in episodes of streptococcal pharyngitis and acute otitis media. No protection against scarlet fever was detected. SN - 2284-0729 UR - https://www.unboundmedicine.com/medline/citation/27874935/Effect_of_administration_of_Streptococcus_salivarius_K12_on_the_occurrence_of_streptococcal_pharyngo_tonsillitis_scarlet_fever_and_acute_otitis_media_in_3_years_old_children_ DB - PRIME DP - Unbound Medicine ER -